Amgen is expanding in RI with a new $160-million next-gen biomanufacturing plant that will be the first of its kind in the U.S. The facility will be supported by incentives from RI’s innovative economic development programs.

The new biomanufacturing plant will be built on Amgen’s current 75-acre campus in West Greenwich and is expected to create approximately 150 additional highly-skilled manufacturing positions. The new plant will employ Amgen’s next-gen biomanufacturing capabilities and will manufacture products for the U.S. and global markets. Amgen currently employs 625 full-time employees in RI. 

“We are excited that Amgen Rhode Island was chosen as the location to build the new biomanufacturing plant,” said Tia Bush, vice president of Operations at Amgen Rhode Island. “It is a testament to our skilled, dedicated workforce and Amgen’s continued presence in Rhode Island, which will enable ongoing collaborations with local academic institutions and the broader Rhode Island community.”

Amgen will receive tax credits valued at $2.2 million through the Rebuild Rhode Island tax credit program and the Qualified Jobs Incentive Act. There is potential for Amgen to receive an additional $1.25 million upon meeting established performance metrics.

Amgen plans to incorporate multiple innovative technologies into a single facility, which is expected to be built in half the construction time with approximately half of the operating cost required of a traditional plant. Next generation biomanufacturing plants require a smaller manufacturing footprint offering environmental benefits such as reduced water and energy consumption, and lower levels of carbon emissions.